Cleerly Stock

Heart Disease Diagnosis Solutions

Sign up today and learn more about Cleerly Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Cleerly Stock

Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI to offer actionable clinical insights to every stakeholder in the heart care pathway. Through these data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks.

Cleerly is headquartered in New York, NY, and was founded in 2017. Notable investors include Fidelity Management and Research, Novartis, and T. Rowe Price.

Investors

Funding History

April 2020	$11.5M
June 2021	$28.1M
June 2021	$16.8M
February 2022	$230M

Management

Chief Executive Officer

James Min

Chief Medical Officer

James Earls

Press

businesswire - Feb, 22 2024

Cleerly® ISCHEMIA™ Software Device Billable With AMA Category I CPT® Code for Noninvasive Estimates of Fractional Flow Reserve

biospace - Jan, 13 2024

Cleerly® Launches Cleerly® ISCHEMIA™ Solution for Heart Disease Analysis

businesswire - Jun, 21 2023

Cleerly Wins 2023 Artificial Intelligence Breakthrough Award

vator - Feb, 15 2023

Cleerly partners with ClearDATA to keep patient health data secure

biospace - Dec, 7 2022

Cleerly Hires Udo Hoffmann, MD, MPH as Chief Scientific Officer

Trending Companies

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Join Now

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen Inc. was awarded a 2023 Fintech Breakthrough Award by Tech Breakthrough LLC on or about March 23, 2023, based on the prior calendar year and covering calendar year 2023, and has compensated Tech Breakthrough LLC for use of its name and logo in connection with the award. Tech Breakthrough LLC is a third party and has no affiliation with EquityZen.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2024 EquityZen Inc. All rights reserved.